Analysis of euploidy rates in preimplantation genetic testing for aneuploidy cycles with progestin-primed versus GnRH agonist/antagonist protocol

European Journal of Medical Research

Research

Fang Li¹  Xiaohui Wang²  Ai Ai²  Lu Wang²  Jie Bai²  Jingyun Wang²  Yuan Zhang²  Chen Qian²  Zhiqin Chen² 

[1] Department of Obstetrics and Gynecology, East Hospital, School of Medicine, Tongji University, No. 150 Jimo Road, 200120, Shanghai, People’s Republic of China;Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, 200092, Shanghai, People’s Republic of China;

关键词: Progestin-primed ovarian stimulation;    Euploid blastocyst;    Euploidy rate;    Preimplantation genetic testing for aneuploidy;    Live birth rate;   

DOI  :  10.1186/s40001-023-01000-1

 received in 2022-10-26, accepted in 2023-01-08,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundProgestins can suppress endogenous luteinising hormone (LH) secretion from the pituitary gland and have shown similar efficacy in terms of collecting competent oocytes and embryos; however, some inconsistencies have been proposed regarding the quality of embryos collected with the use of progestins. This study aimed to evaluate euploidy rates and pregnancy outcomes in preimplantation genetic testing for aneuploidy (PGT-A) cycles using the progestin-primed ovarian stimulation (PPOS) protocol versus the gonadotropin-releasing hormone (GnRH) agonist/antagonist protocol.MethodsThis retrospective cohort study included 608 PGT-A cycles: 146 women in the PPOS group, 160 women in the GnRH agonist group, and 302 women in the GnRH antagonist group. This study was performed at the in vitro fertilisation (IVF) centre of Shanghai First Maternity and Infant Hospital between January 2019 and December 2021. Additionally, 267 corresponding first frozen embryo transfer (FET) cycles were analysed to assess pregnancy outcomes.ResultsThe euploid blastocyst rate per injected metaphase II(MII) oocytes (14.60% vs. 14.09% vs. 13.94%) was comparable among the three groups (p > 0.05). No significant differences were observed among the three groups regarding pregnancy outcomes, including biochemical pregnancy, clinical pregnancy, ongoing pregnancy, implantation, miscarriage, ectopic pregnancy, and live birth rates per transfer in the first FET cycles (p > 0.05).ConclusionsThe PPOS protocol had no negative effect on euploid blastocyst formation, and the pregnancy outcomes in FET cycles using the PPOS protocol were similar to those of the GnRH agonist and antagonist protocols.Trial registration This trial was retrospectively registered

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq337.gif